3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Endometrial Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
4
Head and Neck Neoplasms
3
Breast Neoplasms
3
Rectal Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lung Neoplasms
1
Hemangiosarcoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Adenocarcinoma, Clear Cell
1
Interventions
Cyclophosphamide
25
fludarabine
19
Dexamethasone
17
pembrolizumab
13
Rituximab
12
venetoclax
9
Lenalidomide
9
Gemcitabine
9
Etoposide
9
pomalidomide
8
Vincristine
7
glofitamab
6
fludarabine phosphate
6
carfilzomib
6
Temozolomide
6
obinutuzumab
5
daratumumab
5
Prednisone
5
Nivolumab
5
Doxorubicin
5
Cisplatin
5
Calcium Dobesilate
5
Bortezomib
5
zanubrutinib
4
selinexor
4
Immunotherapy, Adoptive
4
Cytarabine
4
Carboplatin
4
Azacitidine
4
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
dostarlimab
×
90 days
×
Clear all
No trials found.